ABCLAbCellera Biologics Inc.

$1B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$29M-24.2% YoY

Gross Profit

$29M100.0% margin

Operating Income

-$315M-1091.7% margin

Net Income

-$163M-564.8% margin

EPS (Diluted)

$-0.55

Cash Flow

Operating Cash Flow

-$109M

Free Cash Flow

-$187M

Stock-Based Comp.

$68M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$304M

Stockholders' Equity

$1.1B

Cash & Equivalents

$156M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$29M	$38M	-24.2%
Gross Profit	$29M	$38M	-24.2%
Operating Income	-$315M	-$237M	-32.7%
Net Income	-$163M	-$146M	-11.2%

ABCL FY 2024 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena